SEP - 3 2009



510(k) Summary StaXx[®] XD System

Submitter Information

Spine Wave, Inc.
Three Enterprise Drive
Suite 210
Shelton, CT 06484

Telephone: 203-712-1839 Telefax: 203-944-9493

Contact:
Date Prepared:

Roaida Rizkallah August 26, 2009

Device Information

Trade name:

StaXx® XD System

Common name:

Vertebral Body Replacement Class II per 21 CFR 888.3070

Classification:

Classification Name: Spinal Intervertebral Body Fixation Orthosis

Product Code:

MOP

Device Description

The StaXx® XD System is a vertebral body replacement device composed of wafers that are stacked into an expandable implant to adjust its height. The implant components are manufactured from PEEK-OPTIMA with 6% Barium Sulfate. The system also includes a delivery device to implant and expand the implant. The device is offered in sizes ranging from 7mm to 30mm.

Intended Use

The StaXx® XD System is a vertebral body replacement device intended for use in the thoracolumbar spine (T1-L5) to replace and restore height of a collapsed, damaged, or unstable vertebral body or portion thereof, due to tumor or trauma (i.e., fracture). The system is to be placed bilaterally and used with autograft or allograft and supplemental spinal fixation. The supplemental fixation system that is intended to be used with the StaXx® XD System is the CapSure® PS Spine System.

Substantial equivalence

The $StaXx^{\otimes}XD$ System described in this submission is substantially equivalent to the following device:

| Predicate Device | Manufacturer | 510(k) No. |
|------------------|------------------|------------|
| StaXx® XD System | Spine Wave, Inc. | K052670 |

In addition, mechanical testing demonstrated that the StaXx® XD System is equivalent to its predicate device. The minor differences between the StaXx® XD System and the predicate device do not raise any new questions of safety or effectiveness. Thus, the StaXx® XD System is substantially equivalent to its predicate device.

DEPARTMENT OF HEALTH & HUMAN SERVICES



Food and Drug Administration 10903 New Hampshire Avenue Document Mail Center - WO66-G609 Silver Spring, MD 20993-0002

Spine Wave, Inc. % Ms. Roaida Rizkallah Senior Regulatory Affairs Specialist 2 Enterprise Drive, Suite 210 Shelton, Connecticut 06484

SEP - 3 2009

Re: K090315

Trade/Device Name: StaXx® XD System Regulation Number: 21 CFR 888.3060

Regulation Name: Spinal intervertebral body fixation orthosis

Regulatory Class: II Product Code: MQP Dated: August 26, 2009 Received: August 31, 2009

Dear Ms. Rizkallah:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Mark N. Melkerson

Director

Division of Surgical, Orthopedic, and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

| 510(k) Number (if | known): | <u>K090315</u> | | |
|--|--|--|---|--|
| Device Name: | StaXx [®] XD | System | | • |
| Indications for Use | : | | | |
| The StaXx® XD Sy thoracolumbar spin unstable vertebral by system is to be placed spinal fixation. The StaXx® XD System | ne (T1-L5) to reploody or portion the code of the code | lace and restore hereof, due to to d used with aut ixation system | height of a collaps mor or trauma (i.e ograft or allograft a that is intended to b | ed, damaged, or ., fracture). The and supplemental |
| | | | • | 5.7 ₁ |
| Prescription U (Part 21 CFR | Use $\sqrt{}$ 801 Subpart D) | AND/OR | Over-The-Count (21 CFR 801 Su | |
| (PLEASE DO NO |)T WRITE BELO | OW THIS LINI OF NEEDEI | E-CONTINUE ON D) | ANOTHER PAGE |
| Cor | ncurrence of CDI | RH, Office of D | evice Evaluation (| ODE) |
| | | | | |
| Div | wision Sign-Off) ision of Surgical, I Restorative Dev | Orthonedic | MXM | Page <u>1</u> of <u>1</u> |
| 5100 | (k) Number Ko | 90315 | · | |